BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Kemas kini terakhir: 5 jam lalu

51.95

0.99 (1.94%)

  • 1H 1.94%
  • 5H 5.48%
  • 1B 13.95%
  • 6B 8.34%
  • Tahun Ke Tarikh -8.52%
  • 1T -11.00%
  • 5T -16.63%
Penutupan Terdahulu 50.96
Buka 50.80
Jumlah Dagangan 20,461,111
Purata Dagangan (3B) 16,040,112
Modal Pasaran 105,757,376,512
Harga / Pendapatan (P/E TTM) 17.49
Harga / Pendapatan (P/E Ke hadapan) 8.13
Harga / Jualan (P/S) 2.09
Harga / Buku (P/B) 5.40
Julat 52 Minggu
42.52 (-18%) — 63.33 (21%)
Tarikh Pendapatan 30 Oct 2025
Hasil Dividen (DY TTM) 1.19%
Margin Keuntungan 11.38%
Margin Operasi (TTM) 31.57%
EPS Cair (TTM) 2.68
Pertumbuhan Hasil Suku Tahunan (YOY) -5.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -95.90%
Jumlah Hutang/Ekuiti (D/E MRQ) 293.85%
Nisbah Semasa (MRQ) 1.28
Aliran Tunai Operasi (OCF TTM) 14.31 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 13.93 B
Pulangan Atas Aset (ROA TTM) 7.24%
Pulangan Atas Ekuiti (ROE TTM) 31.99%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Bristol-Myers Squibb Company Menaik Menurun

AISkor Stockmoo

0.1
Konsensus Penganalisis -1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -1.0
Purata Bergerak Teknikal 1.0
Osilator Teknikal 2.0
Purata 0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BMY 106 B 1.19% 17.49 5.40
JNJ 488 B 0.61% 19.56 6.24
ABBV 402 B 1.44% 172.39 50.46
MRK 252 B 1.60% 13.36 4.55
PFE 146 B 1.67% 14.94 1.55
GSK 97 B 0.81% 13.71 4.52

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.07%
% Dimiliki oleh Institusi 82.11%

Pemilikan

Nama Tarikh Syer Dipegang
Independent Franchise Partners Llp 30 Sep 2025 20,623,351
Julat 52 Minggu
42.52 (-18%) — 63.33 (21%)
Julat Harga Sasaran
45.00 (-13%) — 57.00 (9%)
Tinggi 57.00 (Goldman Sachs, 9.72%) Pegang
Median 51.00 (-1.83%)
Rendah 45.00 (Citigroup, -13.38%) Pegang
Purata 51.00 (-1.83%)
Jumlah 2 Pegang
Harga Purata @ Panggilan 47.53
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Goldman Sachs 02 Dec 2025 57.00 (9.72%) Pegang 48.25
Citigroup 17 Nov 2025 45.00 (-13.38%) Pegang 46.81

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
03 Dec 2025 Pengumuman Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
03 Dec 2025 Pengumuman Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
01 Dec 2025 Pengumuman Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
26 Nov 2025 Pengumuman Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
24 Nov 2025 Pengumuman Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
24 Nov 2025 Pengumuman Bristol Myers Squibb to Host Hematology-Focused Investor Event
18 Nov 2025 Pengumuman Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
17 Nov 2025 Pengumuman Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
14 Nov 2025 Pengumuman Update on Phase 3 Librexia ACS Trial
12 Nov 2025 Pengumuman Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
05 Nov 2025 Pengumuman Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
03 Nov 2025 Pengumuman Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
03 Nov 2025 Pengumuman Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
30 Oct 2025 Pengumuman Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
27 Oct 2025 Pengumuman Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
25 Oct 2025 Pengumuman Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
17 Oct 2025 Pengumuman SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
14 Oct 2025 Pengumuman insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform
13 Oct 2025 Pengumuman Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
13 Oct 2025 Pengumuman SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
10 Oct 2025 Pengumuman Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
10 Oct 2025 Pengumuman Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
01 Oct 2025 Pengumuman Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease
25 Sep 2025 Pengumuman Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
23 Sep 2025 Pengumuman Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
19 Sep 2025 Pengumuman Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
17 Sep 2025 Pengumuman Advancing Cancer Research Brings New Hope for Patients Worldwide
17 Sep 2025 Pengumuman Bristol Myers Squibb Announces Dividend
16 Sep 2025 Pengumuman Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
Papar semua
Hasil Dividen (DY TTM) 1.19%
Purata Hasil Dividen 5T 3.55%
Nisbah Pembayaran 91.04%
Jangkaan Pembayaran Dividen Seterusnya Feb 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
03 Jan 2025 11 Dec 2024 03 Feb 2025 0.62 Tunai
04 Oct 2024 10 Sep 2024 01 Nov 2024 0.6 Tunai
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 Tunai
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 Tunai
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 Tunai
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 Tunai
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 Tunai
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 Tunai
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 Tunai
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 Tunai
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 Tunai
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 Tunai
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 Tunai
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 Tunai
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 Tunai
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 Tunai
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 Tunai
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 Tunai
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 Tunai
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 Tunai
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 Tunai
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 Tunai
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 Tunai
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 Tunai
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 Tunai
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 Tunai
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 Tunai
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 Tunai
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 Tunai
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 Tunai
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 Tunai
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 Tunai
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 Tunai
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 Tunai
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 Tunai
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 Tunai
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 Tunai
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 Tunai
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 Tunai
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 Tunai
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 Tunai
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 Tunai
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 Tunai
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 Tunai
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 Tunai
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 Tunai
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 0.620 1 1.19
2024 2.40 4 4.24
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda